Bristol-Myers Squibb Company / Padlock Therapeutics, Inc.

Rheumatoid Arthritis (and other autoimmune diseases — SLE, MS)

Disease Overview

Rheumatoid arthritis is a chronic autoimmune disease in which the immune system attacks the synovial joints, driving inflammation, joint destruction and disability. Despite TNF inhibitors and biologics, a meaningful share of patients fail to reach durable remission, motivating research into upstream mechanisms such as citrullination — the post-translational modification driven by PAD enzymes that generates the autoantigens recognized in seropositive RA.

Competitive Landscape

By 2016 the RA market was dominated by anti-TNF biologics — AbbVie's Humira (adalimumab, ~$16B WW in 2016), Amgen's Enbrel (etanercept) and J&J's Remicade (infliximab) — alongside BMS's own Orencia (abatacept, $1.885B in 2015), Roche's Actemra (tocilizumab) and Pfizer's Xeljanz (tofacitinib) JAK inhibitor. Despite this depth, ~30% of RA patients still fail multiple biologics, leaving a clear unmet need for disease-modifying mechanisms that interrupt autoimmunity earlier. Padlock's PAD/PAD4 inhibitors targeted the enzyme that citrullinates self-proteins to create the anti-CCP autoantigens central to seropositive RA pathogenesis. The deal mattered for BMS because it complemented Orencia's T-cell co-stimulation blockade with a potential disease-modifying small molecule, addressing patients with rapidly progressive disease and aggressive autoantibody profiles. Competing PAD4 efforts came from Bristol's own discovery work and academic groups; the Padlock acquisition gave BMS exclusivity in this mechanism. By 2024 BMS appeared to have pivoted from Padlock's small-molecule chemistry toward PAD4 antibodies, suggesting the original chemistry program did not generate a clinical small-molecule candidate.